menu
    • menu
    [{"orgOrder":0,"company":"Oncology Pharma","sponsor":"NanoSmart Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Dactinomycin","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncology Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oncology Pharma \/ Oncology Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Oncology Pharma \/ Oncology Pharma"},{"orgOrder":0,"company":"Oncology Pharma","sponsor":"Oncology Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Erlotinib","moa":"||Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Undisclosed","graph3":"Oncology Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oncology Pharma \/ Oncology Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Oncology Pharma \/ Oncology Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Oncology Pharma

    Menu

    Oncology Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oncology Pharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Oncology Pharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dactinomycin

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : NanoSmart Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals for Initial Phases of IND-Enabling A...

                            Details : The licensed technology possesses proprietary technology and intellectual property rights for the development of pharmaceutical drug formulations that are liposomal and/or emulsion-based formulations and that may incorporate Anti-Nuclear Antibodies (ANA)...

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            March 31, 2021

                            Lead Product(s) : Dactinomycin

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : NanoSmart Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oncology Pharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Oncology Pharma

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Erlotinib,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Sybleu

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Oncology Pharma Signs Licensing Deal with Sybleu to market a Chemotherapeutic Agent in Combination with a Bioa...

                            Details : The chemotherapeutic agent of claim is AQ4 & AQ4N. The bioactive agent is derived from the group of TNF-alpha, GM-CSF, IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40 Ligand.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 26, 2021

                            Lead Product(s) : Erlotinib,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Sybleu

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth